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Visual and treatment outcomes of tubercular 
uveitis: a prospective case series from a referral 
hospital in Pakistan
Muhammad Ishaq Ghauri1, Nousheen Iqbal1,2* , Syeda Urooj Riaz1, Muhammad Irfan2, Ajeet Kumar1 
and Muhamad Shariq Mukarram1
Abstract 
Objective: Pakistan is the fifth highest TB burden country. Tuberculous uveitis (TbU) is a form of extrapulmonary TB, 
that is not uncommon in high burden country but very limited data is available on its outcome. The aim of the study 
is to assess the outcome of TbU with anti-tuberculous treatment (ATT).
Results: A prospective study was conducted at Jinnah Medical College Hospital (JMCH) Karachi, Pakistan from July 
to December 2017. Patients with suspected TbU were started on standard ATT chemotherapy for 12 months. Their 
response was assessed via slit lamp examination and visual acuity at 1, 3, 6 and 12 months of treatment. Forty patients 
with probable TbU were treated with ATT, mean age was 36 ± 3 years and 24 (60%) were females. Around 26 (65%) 
had Monteux test of 15 mm or more. History of TB contact was positive in 24 (60%) and 12 (30%) had previous history 
of TB. All patients complained for blurring of vision and floaters. Posterior uveitis seen in 36 (90%) of patients. Com-
plete response achieved in 32 (80%) after ATT while 6 (14%) had changed in inflammation and 2 (6%) had no benefit.
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Introduction
Tuberculosis (Tb) is a leading cause of mortality and mor-
bidity worldwide, especially in South East Asia regions 
which carries high burden of Tb. Tb can involve any part 
of the body, it causes both pulmonary and extrapulmo-
nary diseases. Tb is preventable and completely curable 
disease despite of this an estimated 1.3 million deaths 
among HIV negative caused in 2017 [1]. Pakistan is the 
fifth highest Tb burden country worldwide.
Tuberculous uveitis (TbU) is a rare entity of extra pul-
monary Tb where uveal track involvement is common. It 
causes granulomatous anterior uveitis, disseminated cho-
roiditis with vitritis, and cystoid macular edema [2]. TbU 
sometimes manifest with non-specific features ranging 
from non-granulomatous anterior uveitis to occlusive 
retinal vasculitis [3]. Prevalence of TbU is variable in 
different parts of world, being more common in south 
East Asia. A study from Pakistan showed that granu-
lomatous diseases are the frequent cause of uveitis likely 
because of high burden of Tb [4].
Tuberculous uveitis is a great mimicker of many dis-
eases [5]. Diagnosis is usually presumptive because of 
variable presentation and difficulty in obtaining culture 
and histopathology tissues [6]. Diagnosis requires a high 
index of suspicion and is made by exclusion of other 
causes of uveitis like sarcoidosis and autoimmune dis-
eases. The diagnosis of TbU can be confirmed by finding 
caseating granuloma, acid-fast bacilli on histopathology 
of ocular tissues and on isolation of the organism on AFB 
culture or by Nucleic acid amplification tests. Usually 
histopathologic specimens reveals a paucity of organ-
isms [7]. The absence of pulmonary Tb does not rule out 
the possibility of ocular Tb, as majority of patients with 
extrapulmonary Tb have no evidence of active pulmo-
nary TB [2, 8].
Tuberculous uveitis is treated with standard antitu-
berculous therapy (ATT), 2  months of intensive phase 
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followed by 10  months of continuous phase combined 
with systemic corticosteroids till clinical response is seen 
then tapered off [2]. There is paucity of data from our 
country on TbU outcomes likely because of underreport-




An observational prospective study was conducted on 
patients with TbU at JMCH Karachi, Pakistan from July 
to December 2017. JMCH is a 500 bed teaching hospital 
spread over 6 acres of land in Korangi, Karachi Pakistan. 
TbU patients were referred for treatment after TBU diag-
nosis by an ophthalmologist from Layton Rahmatullah 
Benevolent Trust (LRBT). LRBT is a charitable eye hospi-
tal and Pakistan’s largest non-governmental organization 
established in 1984. These patients presented at LRBT 
with complain of blurring of vision, photophobia, pain, 
redness, floaters or photophia. Patients with suspected 
of uveitis underwent detailed history, general and slit 
lamp examination. Then they were classified according 
to standardization of Uveitis Nomenclature (SUN) work-
shop [9] classification into anterior, Intermedia and pos-
terior uveitis. TB uveitis was defined as an unexplained 
uveitis after thorough diagnostic workup, and/or ocular 
abnormalities compatible with TB, and/or abnormalities 
on chest radiology compatible with TB.
The patient were also inquired about history of fever, 
weight loss, history of Tb contact in family, previ-
ous history of Tb and associated symptoms. A detailed 
physical examination was done. All patients were investi-
gated at baseline with chest xray, ESR and Montoux test 
(MT). Patients with TbU were started on ATT (usually 
2 months of rifampicin, isoniazid, pyrizinamide, and eth-
ambutol followed by months of rifampicin and isonia-
zid for total of 1  year duration). Clinical response was 
assessed by ophthalmologist at LRBT through slit lamp 
examination and visual acuity at 1, 3, 6 and 12  months 
followup. Informed consent was obtained from all 
patients or the attendant next of kin. JMCH ethical 
review committee approved study protocol before the 
commencement of the study. All data was collected on 
predesigned performa.
Statistical analysis
All analyses were conducted by using the SPSS (Release 
19.0, standard version, copyright © SPSS; 1989–2002). 
A descriptive analysis was performed for demographic 
features presented as mean ± SD for quantitative vari-
able that is age. Number (percentage) for qualitative 
variables that is, gender, history of TB, type of uveitis 
and outcome of uveitis that included change in inflation 
complete resolution and no change was done.
Results
A total of 40 cases of TbU was referred to our center 
for treatment during the study time period. Mean age 
was 36 ± 3 years, 24 (60%) were female and 24 (60%) of 
patient had a family history of Tb. Blurring of vision 
and floaters was reported in 40 (100%) of patients fol-
lowed by decrease vision and eye redness (Table  1). 
Patients with decrease vision had visual acuity of 6/18 
and 6/36 at the start of treatment and at the end of 
treatment visual acuity corrected to 6/6 in all of these 
patients.
Abnormal chest x-ray finding was present in 12 
(30%) of patients, which included nodular infiltrates 
in 6 patients, upper lobe cavitation in 2 patients and 4 
patients had bilateral hilar lymphadenopathy. Steroids 
were received by 3 (7.5%) patients where there was evi-
dence of acute vitritis suggested by an ophthalmologist. 
Prednisolone was given in a dose of 1 mg/kg given for 
3 weeks, then tapered off, according to the response to 
the treatment. We found posterior uveitis as the com-
monest form of TbU (90%). After taking 12 months of 
standard ATT 32 (80%) of patients had complete reso-
lution of symptoms, 14% had partial resolution while 
the 2 (6%) had no improvement on treatment (Table 2).
Table 1 Baseline characteristics of patients with TbU
* Received prior ATT 
Demographics Frequency (n = 40)
Mean age 36 ± 3 years
Gender
 Male 16 (40%)
 Female 24 (60%)
 Previous history of TB* 12 (30%)
 Family history of TB 24 (60%)
Montoux test (mm)
 < 15 14 (35%)
 > 15 26 (65%)
ESR (mm)
 < 60 10 (25%)
 > 60 30 (75%)
Symptom
 Redness of eye 24 (60%)
 Eye pain 6 (15%)
 Photophobia 12 (30%)
 Blurred vision 40 (100%)
 Dark, floating spots in field of vision (floaters) 40 (100%)
 Decreased vision 24 (60%)
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Discussion
In this study, we found that posterior uveitis is the com-
monest TbU presentation in our patients. Overall, our 
patient population had a good clinical response and 
complete recovery on standard ATT. We found posterior 
uveitis in 90% of our patients, which is similar to the data 
from India [5, 10]. However, data from developed coun-
tries is different, a study from the Netherlands exclusively 
studied TbU and found Panuveitis in 51.5%, followed by 
posterior uveitis 30.3% [11]. Another study from the UK 
found chronic Panuveitis as commonest TbU [3] may be 
because of difference of population and regions.
Many patients also had no history of pulmonary or 
extrapulmonary Tb other than uveitis [2] as seen in our 
patients where only few patients had an abnormal Chest 
x ray which was found on routine work-up with no com-
plaints of cough and sputum production. As Pakistan is a 
Tb endemic country we found that majority patient had 
a positive TB contact history, which can be an important 
clue in such patients when suspecting TbU as seen previ-
ously in a study from Iraq [12].
Tuberculin skin testing TST or MT was done in all 
patients and was found > 15 mm induration in the major-
ity of patients of TbU. These results are similar to the 
study published from Iraq, where they also found sig-
nificant high induration in ocular TB [13]. However, this 
testing has limitation in developing countries as MT is 
positive in the general population. Along with MT we 
also found higher ESR in our patients. Complete recovery 
seen in 80% of our patients compared to previous studies 
where the success rate was 70%, 70% and 60% respectively 
[3, 11, 14]. While all patients had favorable outcomes 
with no recurrence of disease in a study from Iraq [13]. 
Two of our patients had no response to treatment that 
may be because of underlying fibrosis or delayed in seek-
ing medical treatment. Three of our patients received 
corticosteroids with signs of acute vitritis. The use of sys-
temic steroids is controversial [15] they are usually added 
to treat inflammation and macular edema [16]. The pos-
terior uveitis was seen commonly in our study followed 
by pan uveitis. This is reported to be commonest form of 
uveitis from India in TB uveitis [2, 5] while study from 
Saudia, Italian and Swiss center showed pan uveitis fol-
lowed by posterior uveitis in presumed TbU [8, 17].
Conclusion
In high burden countries, the TbU should be suspected 
among patients presenting with symptoms of blurring of 
vision, floaters, decrease vision and eye redness, treat-
ment with ATT has a favorable outcome. It is important 
to diagnose TbU timely to prevent permanent damage 
and visual loss. Although it remains difficult to diagnose, 
early recognition of the correct diagnosis and specific 
therapy avoids recurrences, improves visual acuity and 
intra-ocular inflammation.
Limitations
This study showed TbU experience in term of its treat-
ment outcome. However, it has some limitations, (1) it’s 
a single center study, (2) limited number of patients, (3) 
there is always limitation in diagnosing TbU, diagno-
sis was based on history and examination while GenX-
pert testing was not done. Large multicenter studies are 
required to study further patient characteristics and clin-
ical response in Tb endemic countries like Pakistan.
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Table 2 Type and  outcome of  Tb uveitis among  study 
population
Type of uveitis Percentage
Pan uveitis 10% (4)
Anterior uveitis 0%
Intermediate uveitis 0%
Posterior uveitis 90% (36)
Outcome Frequency
Resolved 32 (80%)
Change in inflammation 6 (14%)
No change 2 (6%)
Page 4 of 4Ghauri et al. BMC Res Notes          (2019) 12:404 
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
Ethics approval and consent to participate
Ethical approval was taken from Jinnah Medical College Hospital Ethical 





The authors declare that they have no competing interests.
Author details
1 Department of Medicine, Jinnah Medical College Hospital, Karachi, Pakistan. 
2 Section of Pulmonary and Critical Care Medicine, Department of Medicine, 
Aga Khan University, Stadium Road, Karachi, Pakistan. 
Received: 24 April 2019   Accepted: 5 July 2019
References
 1. Global tuberculosis report 2018. World health organization WHO. https ://
www.who.int/tb/publi catio ns/globa l_repor t/en/. Accessed Jan 2019.
 2. Abu El-Asrar AM, Abouammoh M, Al-Mezaine HS. Tuberculous 
uveitis. Middle East Afr J Ophthalmol. 2009;16(4):188–201. https ://doi.
org/10.4103/0974-9233.58421 .
 3. Sanghvi C, Bell C, Woodhead M, Hardy C, Jones N. Presumed tuberculous 
uveitis: diagnosis, management, and outcome. Eye. 2011;25(4):475–80. 
https ://doi.org/10.1038/eye.2010.235.
 4. Muhammad I, Jibran SM, Khalid M. Uveitis is not just an ophthalmologists’ 
concern. JPMA. 2012;62(2):92.
 5. Shakarchi FI. Ocular tuberculosis: current perspectives. Clin Ophthalmol. 
2015;9:2223–7. https ://doi.org/10.2147/opth.s6525 4 (eCollection 2015).
 6. Varma D, Anand S, Reddy AR, et al. Tuberculosis: an under-diagnosed 
aetiological agent in uveitis with an effective treatment. Eye. 
2006;20:1068–73.
 7. Wroblewski KJ, Hidayat AA, Neafie RC, Rao NA, Zapor M. Ocular 
tuberculosis: a clinicopathologic and molecular study. Ophthalmology. 
2011;118:772–7.
 8. Cimino L, Herbort CP, Aldigeri R, Salvarani C, Boiardi L. Tuberculous 
uveitis: a resurgent and under diagnosed disease. Int Ophthalmol. 
2009;29(2):67–74.
 9. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis 
nomenclature for reporting clinical data. Results of the First International 
Workshop. Am J Ophthalmol. 2005;140:509–16.
 10. Gupta V, Gupta A, Rao NA. Intraocular tuberculosis: an update. Surv 
Ophthalmol. 2007;52:561–87.
 11. Vos AG, Wassenberg MW, de Hoog J, Oosterheert JJ. Diagnosis and 
treatment of tuberculous uveitis in a low endemic setting. Int J Infect 
Dis. 2013;17(11):e993–9. https ://doi.org/10.1016/j.ijid.2013.03.019 (Epub 
2013 May 22).
 12. Al-Shakarchi F. Mode of presentations and management of pre-
sumed tuberculous uveitis at a referral center. Iraqi Postgrad Med J. 
2015;14(1):91–5.
 13. Al-Shakarchi FI. Pattern of uveitis at a referral center in Iraq. Middle East 
Afr J Ophthalmol. 2014;21:291–5.
 14. Gineys R, Bodaghi B, Carcelain G, Cassoux N, le Boutin TH, Amoura Z, 
et al. QuantiFERON-TB gold cut-off value: implications for the manage-
ment of tuberculosis-related ocular inflammation. Am J Ophthalmol. 
2011;152(433):440.e1.
 15. Rao NA, Saraswathy S, Smith RE. Tuberculous uveitis: distribution of 
mycobacterium tuberculosis in the retinal pigment epithelium. Arch 
Ophthalmol. 2006;124:1777–9.
 16. Alvarez GG, Roth VR, Hodge W. Ocular tuberculosis: diagnostic and treat-
ment challenges. Int J Infect Dis. 2009;13:432–5.
 17. Al-Mezaine HS, Al-Muammar A, Kangave D, Abu El-Asrar AM. Clinical 
and optical coherence tomographic findings and outcome of treat-
ment in patients with presumed tuberculous uveitis. Int Ophthalmol. 
2008;28:413–23.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
